/BHC
BHC Stock - Bausch Health Companies Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNYSE
$6.88+0.88%
+$0.06 (+0.88%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.74
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).83
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+16.3%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BHC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.81 – $6.95
TARGET (TP)$8.00
STOP LOSS$6.33
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.41
52W High$8.69
52W Low$4.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.63B | $8.76B | $8.12B | $8.43B | $8.03B |
| Gross Profit | $6.84B | $6.20B | $5.76B | $6.04B | $5.78B |
| Gross Margin | 71.1% | 70.8% | 70.9% | 71.6% | 72.0% |
| Operating Income | $1.55B | $963.00M | $454.00M | $450.00M | $676.00M |
| Net Income | $-46,000,000 | $-592,000,000 | $-225,000,000 | $-948,000,000 | $-559,000,000 |
| Net Margin | -0.5% | -6.8% | -2.8% | -11.2% | -7.0% |
| EPS | $-0.13 | $-1.62 | $-0.59 | $-2.61 | $-1.57 |
Company Overview
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
25%
Hold / Neutral
3
75%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish3 Neutral/Bearish
Price Targets
$9
Average Target
↑ 26.0% Upside
Now
$3
Low
$9
Average
$16
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Equal Weight | $8 |
| August 2nd 2024 | Piper Sandler | Downgrade | Underweight | $3← $9 |
| July 10th 2024 | Raymond James | Initiation | Market Perform | $8 |
| September 20th 2023 | Jefferies | Upgrade | Buy | $16← $9 |
| June 16th 2023 | TD Cowen | Downgrade | Market Perform | - |
| July 29th 2022 | Truist | Downgrade | Hold | - |
| July 29th 2022 | RBC Capital Mkts | Downgrade | Sector Perform | $5← $12 |
| July 28th 2022 | JP Morgan | Downgrade | Neutral | - |
| June 13th 2022 | JP Morgan | Resumed | Overweight | $12 |
Earnings History & Surprises
BHCBeat Rate
56%
Last 18 quarters
Avg Surprise
-6.4%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$1.16
Q4 2025
EPS Surprise History
Q1 24
+13.9%
$1.15vs$1.01
Q2 24
-21.3%
$0.59vs$0.75
Q3 24
+1.1%
$0.89vs$0.88
Q4 24
+8.7%
$1.12vs$1.03
Q1 25
-30.3%
$1.15vs$1.65
Q2 25
-28.9%
$0.59vs$0.83
Q3 25
-7.2%
$0.90vs$0.97
Q4 25
+8.4%
$1.16vs$1.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $1.23 | — | — | — |
Q4 2025 | Oct 29, 2025 | $1.07 | $1.16 | +8.4% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.97 | $0.90 | -7.2% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $0.83 | $0.59 | -28.9% | ✗ MISS |
Q1 2025 | Feb 19, 2025 | $1.65 | $1.15 | -30.3% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $1.03 | $1.12 | +8.7% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $0.88 | $0.89 | +1.1% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $0.75 | $0.59 | -21.3% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $1.01 | $1.15 | +13.9% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.92 | $1.03 | +12.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $0.75 | $0.81 | +8.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.75 | $0.52 | -30.7% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $0.92 | $1.02 | +10.9% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.92 | $0.76 | -17.4% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $0.89 | $0.55 | -38.2% | ✗ MISS |
Q2 2022 | May 10, 2022 | $1.03 | $0.72 | -30.1% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $1.08 | $1.27 | +17.6% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $1.07 | $1.14 | +6.5% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.97 | $0.98 | +1.0% | ✓ BEAT |
Latest News
Barclays Initiates Coverage On Bausch Health Companies with Equal-Weight Rating, Announces Price Target of $8
➖ NeutralBenzinga•Dec 9, 2025, 03:29 PM•Also:
Bausch Health shares are trading higher after the company announced its global aesthetic business, Solta Medical, acquired Wuhan Shibo Zhenmei Technology.
📈 PositiveBenzinga•Dec 1, 2025, 03:45 PM
Bausch Health Companies And Its Global Aesthetic Business, Solta Medical, Acquired Wuhan Shibo Zhenmei Technology, Consisting Of The Shibo Group's Aesthetics Distribution Business, Deal Terms Were Not Disclosed
➖ NeutralBenzinga•Dec 1, 2025, 12:15 PM
Bausch Health announced an exchange offer for up to $1.6 billion of its 4.875% and 11.00% Senior Secured Notes due 2028, swapping them for new 10.00% Senior Secured Notes due 2032 issued by its wholly-owned subsidiary
➖ NeutralBenzinga•Nov 24, 2025, 12:19 PM
Bausch + Lomb Program Recycles Nearly 700,000 Pounds of Contact Lens Waste
📈 PositiveBenzinga•Nov 10, 2025, 12:15 PM
Bausch Health shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.
📈 PositiveBenzinga•Oct 30, 2025, 10:40 AM
Bausch Health rises on 2025 revenue, EBITDA guidance boost, Q3 beats
📈 PositiveSeeking Alpha•Oct 29, 2025, 09:53 PM
Bausch Health shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.
📈 PositiveBenzinga•Oct 29, 2025, 08:33 PM
Bausch Health Companies Q3 Adj. EPS $1.16 Beats $1.13 Estimate, Sales $2.681B Beat $2.637B Estimate
📈 PositiveBenzinga•Oct 29, 2025, 08:26 PM
Bausch Health Companies Raises FY2025 Sales Guidance from $10.000B-$10.250B to $10.050B-$10.250B vs $10.141B Est
📈 PositiveBenzinga•Oct 29, 2025, 08:09 PM
Cooper Companies shares are trading higher after The Wall Street Journal reported that Jana Partners built a stake in the company and that Bausch + Lomb's CEO expressed interest in combining with Cooper's contact-lens unit.
📈 PositiveBenzinga•Oct 20, 2025, 11:44 AM•Also:
The Wall Street Journal Reported Sunday, Jana Partners Builds Stake In Cooper Cos; Bausch + Lomb CEO Says He Is Interested in Combination With Cooper's Contact-Lens Unit
📈 PositiveBenzinga•Oct 20, 2025, 08:52 AM•Also:
Bausch Health Shareholders Approve Amended And Restated Shareholder Rights Plan Agreement
📈 PositiveBenzinga•Oct 9, 2025, 11:13 AM
Bausch + Lomb Reports enVista Envy Intraocular Lens Met All Primary Efficacy And Safety Endpoints In Multicenter US Study
📈 PositiveBenzinga•Sep 11, 2025, 11:04 AM
Bausch + Lomb Study Shows XIIDRA 5% Eases End-Of-Day Dryness In Contact Lens Wearers, Published In Clinical Ophthalmology
📈 PositiveBenzinga•Sep 9, 2025, 11:18 AM
Bausch + Lomb Announces U.S. Launch Of ASANA Gas Permeable Lenses
📈 PositiveBenzinga•Sep 8, 2025, 11:09 AM•Also:
Bausch Health's Triple-Combination Acne Gel CABTREO Now Covered By Quebec And Saskatchewan Drug Plans
📈 PositiveBenzinga•Aug 21, 2025, 12:09 PM
Bausch + Lomb drops after guidance cut amid enVista recall
📉 NegativeSeeking Alpha•Apr 30, 2025, 04:16 PM
Notable healthcare headlines for the week: Merck, Roche and Bausch Health in focus
➖ NeutralSeeking Alpha•Apr 27, 2025, 06:10 PM•Also: ,
Bausch Health jumps after Carl Icahn's 34% stake
📈 PositiveSeeking Alpha•Apr 22, 2025, 12:18 PM
Frequently Asked Questions about BHC
What is BHC's current stock price?
Bausch Health Companies Inc. (BHC) is currently trading at $6.88 per share. The stock has moved +0.88% today.
What is the analyst price target for BHC?
The average analyst price target for BHC is $8.00, based on 1 analyst.
What sector is Bausch Health Companies Inc. in?
Bausch Health Companies Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NYSE exchange.
What is BHC's market cap?
Bausch Health Companies Inc. has a market capitalization of $2.55 billion, making it a mid-cap company.
Does BHC pay dividends?
No, Bausch Health Companies Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVO
Alvotech
$4.90
Mkt Cap: $1.5B
ANIP
ANI Pharmaceuticals, Inc.
$82.85
Mkt Cap: $1.9B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
CON
Concentra Group Holdings Parent, Inc.
$19.43
Mkt Cap: $2.5B
CPRX
Catalyst Pharmaceuticals, Inc.
$23.74
Mkt Cap: $2.9B
HAE
Haemonetics Corporation
$80.21
Mkt Cap: $3.9B
HCM
HUTCHMED (China) Limited
$13.55
Mkt Cap: $2.4B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
PRGO
Perrigo Company plc
$13.23
Mkt Cap: $1.8B
XRAY
DENTSPLY SIRONA Inc.
$11.21
Mkt Cap: $2.2B
Explore stocks similar to BHC for comparison